CBU
ALXN

CIBC Bank USA’s Alexion Pharmaceuticals ALXN Stock Holding History

CIBC Bank USA’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-2,869
Closed -$547K – 264
2015
Q4 		$547K Sell
2,869
-1
-0% -$175 0.1% 134
2015
Q3 		$450K Buy
2,870
+6
+0.2% +$1.09K 0.08% 155
2015
Q2 		$517K Hold
2,864
– – 0.09% 153
2015
Q1 		$496K Hold
2,864
– – 0.09% 153
2014
Q4 		$530K Hold
2,864
– – 0.09% 163
2014
Q3 		$475K Buy
+2,864
New +$470K 0.09% 176

Other funds holding ALXN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

CIBC Bank USA's ALXN Position: Q1 2016 in Review

CIBC Bank USA sold out of Alexion Pharmaceuticals (ALXN) in Q1 2016, closing a stake of 2,869 shares — an estimated $547K sold.

CIBC Bank USA first reported a position in ALXN in Q3 2014 and held it in 6 quarters. The position peaked at $547K in Q4 2015. 518 funds tracked by Wall St. Rank hold ALXN as of Q1 2016.

  • CIBC Bank USA reported no remaining Alexion Pharmaceuticals position as of Q1 2016 after selling out during the quarter.
  • CIBC Bank USA sold 2,869 Alexion Pharmaceuticals shares in Q1 2016, an estimated $547K.
  • CIBC Bank USA first reported a position in Alexion Pharmaceuticals in Q3 2014 and held it in 6 quarters.
  • CIBC Bank USA's Alexion Pharmaceuticals position peaked at $547K in Q4 2015.
  • 518 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2016.

Based on CIBC Bank USA's 13F filing for Q1 2016, filed 18 Apr 2016.